RNA Polymerase III Inhibitor
RNA Polymerase III Inhibitor
RNA Polymerase III Inhibitor 性质
| 储存条件 | = -70C |
|---|---|
| 溶解度 | 溶于 DMSO（最高 35 mg/ml）或乙醇（升温最高 5 mg/ml） |
| 形态 | 类白色固体 |
| 颜色 | 米白色 |
| 稳定性 | 可在-20°C下的DMSO或乙醇溶液保存长达2个月。 |
| InChI | 1S/C19H15Cl2N3O2S2/c1-11-13-9-12(20)7-8-16(13)27-19(11)15-10-18(24(2)22-15)23-28(25,26)17-6-4-3-5-14(17)21/h3-10,23H,1-2H3 |
| InChIKey | BVBDTTLISMIOJY-UHFFFAOYSA-N |
| SMILES | [S](=O)(=O)(Nc2[n](nc(c2)c3[s]c4c(c3C)cc(cc4)Cl)C)c1c(cccc1)Cl |
RNA Polymerase III Inhibitor 用途与合成方法
Combination of SAHA and ML-60218 produces enhanced suppression of proliferation in human pancreatic adenocarcinoma by impairing cell cycle progression and inducing apoptosis. ML-60218 reverses SAHA-stimulated tRNA expression in PANC-1 and BxPC-3 cells. ML-60218 enhances the ability of HDAC inhibitors to induce apoptosis and cell cycle arrest.
In in vitro transcription assays with purified double-layered particles (DLPs), ML-60218 shows dose-dependent inhibitory activity, indicating the viral nature of its target. ML-60218 is found to interfere with the formation of higher-order structures of VP6, the protein forming the DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-60218-treated DLPs shows dose-dependent structural damage. ML-60218-mediated (10 μM ) viroplasm disruption causes NSP5 dephosphorylation.
RNA Polymerase III Inhibitor 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-122122 | RNA Polymerase III Inhibitor | 577784-91-9 | 1 mg | 600 |
| 2026-09-15 | HY-122122 | RNA Polymerase III Inhibitor | 577784-91-9 | 5 mg | 1500 |
